Pangaea Oncology (PANG) | Stock Overview & Key Data
Pangaea Oncology S.A. | Small-cap | Healthcare
Pangaea Oncology S.A. | Small-cap | Healthcare
Pangaea Oncology Performance Comparison
Stock Range
Today's Range
Low: €1.72
High: €1.72
on August 8, 2025
52 Week Range
Low: €1.47
High: €1.80
on September 30, 2024
on October 21, 2024
All-Time High: €2.97 on November 13, 2017
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€58.6M
EPS
-0.03
P/E Ratio (TTM)
N/A
Forward P/E
-57.33
P/B Ratio
3.22
PEG Ratio
N/A
Div. Yield
N/A
ROE
-29.97%
Beta
0.122
Debt to Equity
23.04
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-20.63%
Profit Margin
-37.18%
Returns and Earnings
Return on Assets (TTM)
-9.44%
Return on Equity (TTM)
-29.97%
EBITDA
€509.2K
Net Income (TTM)
€-5.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.42
Quarterly Revenue Growth (YoY)
139.70%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Pangaea Oncology PANG | 58.60M Small-cap | 0.00% | 1.78% | 1.18% | -1.71% | -2.82% | 17.01% | 17.81% | 59.26% |
| Clinica Baviera S.A CBAV | 698.18M Mid-cap | -1.13% | 0.69% | 17.69% | 25.43% | 39.37% | 52.96% | 113.11% | 393.26% |
| EuroEspes S.A EEP | 6.26M Small-cap | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.85% | 35.00% |
| Grifols, S.A GRF | 7.81B Large-cap | 0.15% | 19.91% | 58.70% | 53.07% | 36.89% | 47.66% | -5.89% | -47.14% |
| Laboratorios ROVI | 2.72B Large-cap | 1.13% | -2.45% | 1.99% | -2.71% | -16.02% | -29.88% | 4.78% | 92.65% |
| Almirall S.A ALM | 2.20B Large-cap | 0.59% | -4.81% | 3.10% | 13.19% | 22.91% | 14.70% | 4.89% | 7.74% |
Ownership & Short Interest
Insider Ownership
77.76%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
539
Average 90-Day Volume
296
Pangaea Oncology Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Pangaea Oncology would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PANG's 52-week high and low?
- In the last 52 weeks, Pangaea Oncology reached a high of €1.80 (on October 21, 2024) and a low of €1.47 (on September 30, 2024).
- What is the market cap and P/E ratio for PANG?
- Curious about Pangaea Oncology's size and valuation? Its market capitalization stands at 58.60M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -57.33.
- Does PANG pay dividends? If so, what's the yield?
- As for dividends, Pangaea Oncology isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Pangaea Oncology's main competitors or similar companies to consider before investing?
When looking at Pangaea Oncology, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Clinica Baviera S.A
CBAV698.18M Healthcare Diagnostics & Research 52.96% 113.11% EuroEspes S.A
EEP6.26M Healthcare Diagnostics & Research 0.00% 3.85% Grifols, S.A
GRF7.81B Healthcare Drug Manufacturers - General 47.66% -5.89% Laboratorios
ROVI2.72B Healthcare Drug Manufacturers - Specialty & Generic -29.88% 4.78% Almirall S.A
ALM2.20B Healthcare Drug Manufacturers - Specialty & Generic 14.70% 4.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Pangaea Oncology S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Pangaea Oncology's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -29.97%, the Debt to Equity ratio from the most recent quarter is 23.04, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for PANG?
- Looking at Pangaea Oncology's growth, its revenue over the trailing twelve months (TTM) was €14M. Compared to the same quarter last year (YoY), quarterly revenue grew by 139.70%, and quarterly earnings saw a YoY growth of N/A.
- How much of PANG stock is held by insiders and institutions?
- Wondering who owns Pangaea Oncology stock? Company insiders (like executives and directors) hold about 77.76% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.